COMMUNIQUÉS West-GlobeNewswire

Aligos Therapeutics Announces Eight Abstracts Accepted for Presentation at the EASL Congress 2025

23/04/2025 - 22:05

SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies [...]

Inotiv, Inc. to Report Fiscal 2025 Second Quarter Financial Results and Host Conference Call on Wednesday, May 7, 2025

23/04/2025 - 22:05

WEST LAFAYETTE, Ind., April 23, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and [...]

Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

23/04/2025 - 22:05

NEEDHAM, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies [...]

Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2025

23/04/2025 - 22:05

Year-over-year revenue grows 8% , operating profit up 14% , non-GAAP operating profit up 13% Operating cash flow of $579 million Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at [...]

OraSure to Announce First Quarter 2025 Financial Results and Host Earnings Call on May 7th

23/04/2025 - 22:05

BETHLEHEM, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering first quarter 2025 financial results and certain business [...]

Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting

23/04/2025 - 22:05

SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for [...]

Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025

23/04/2025 - 22:08

Data from Cohorts 1-3 of trial to be presented in an oral session and poster at the Society for Investigative Dermatology (SID) 2025 Annual Meeting Company to discuss data on its first quarter 2025 business update [...]

Iovance Biotherapeutics Announces Participation in Upcoming Scientific Congresses

23/04/2025 - 22:15

SAN CARLOS, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating [...]

Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative Dermatology

23/04/2025 - 22:15

Quantitative analysis of medical claims indicates an estimated 44,553 to 92,967 diagnosed U.S. patients with lymphatic malformations (LMs) with cutaneous involvement Estimates of annual incidence of LMs with cutaneous [...]

Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting

23/04/2025 - 22:30

WALTHAM, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living [...]

Amedisys Reports First Quarter 2025 Financial Results

23/04/2025 - 22:45

BATON ROUGE, La., April 23, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period ended March 31, 2025. Three-Month Periods Ended March 31, 2025 and 2024 [...]

Jushi Holdings Inc. to Report First Quarter 2025 Financial Results on May 8, 2025

23/04/2025 - 23:00

BOCA RATON, Fla., April 23, 2025 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF) , a vertically integrated, multi-state cannabis operator, announced that it expects to [...]

Aptose Announces Auditor Not Standing for Re-Appointment

23/04/2025 - 23:00

SAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug [...]

Aurora Spine Corporation Schedules Release of Fourth Quarter and Fiscal 2024 Financial Results

23/04/2025 - 23:01

CARLSBAD, California, April 23, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in spine and interventional spine technology that improves spinal [...]

Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025

23/04/2025 - 23:14

ROCKVILLE, Md., April 23, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous [...]

Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM)

23/04/2025 - 23:23

– Significant blood pressure reductions among patients with uncontrolled or resistant hypertension treated with lorundrostat reinforce key role of dysregulated aldosterone in disease onset and progression – – Detailed [...]

OSE Immunotherapeutics annonce la sélection de plusieurs abstracts pour présentation à l’ASCO 2025

23/04/2025 - 18:00

OSE Immunotherapeutics annonce la sélection de plusieurs abstracts pour présentation à l’ASCO 2025 Présentations sur l’actif propriétaire Tedopi® et sur deux inhibiteurs de SIRPα développés en partenariat avec [...]

OSE Immunotherapeutics Highlights Abstracts Selected for Presentation at ASCO 2025

23/04/2025 - 18:00

OSE Immunotherapeutics Highlights Abstracts Selected for Presentation at ASCO 2025 Featuring proprietary asset Tedopi® and two partnered SIRPα inhibitor assets with Boehringer Ingelheim NANTES, France – April 23, 2025, [...]

EssilorLuxottica: Chiffre d’affaires T1 2025 - Forte croissance du chiffre d'affaires au premier trimestre

23/04/2025 - 18:00

Forte croissance du chiffre d'affaires au premier trimestre Chiffre d'affaires du Groupe en hausse de +8,1 % à taux de change courants et de +7,3 % à taux de change constants 1 au T1 Solide croissance des segments [...]